MétaCan
Menu
← Back to cohort

Direct-Acting Antivirals Are not Associated With Early Tumor Recurrence After Curative Treatments in Hepatitis C-related Hepatocellular Carcinoma

2017· article· en· W2911736776 on OpenAlexaff
Yin Chan, Samuel Maclennan, Elijah Dixon, Jason Wong, Mark G. Swain, Carla S. Coffin, Kelly W. Burak

Bibliographic record

VenueThe American Journal of Gastroenterology · 2017
Typearticle
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsFoothills Medical CentreUniversity of Calgary
Fundersnot available
KeywordsMedicineHepatocellular carcinomaInternal medicineGastroenterologyHepatitis CRetrospective cohort studySurgeryOncology

Abstract

fetched live from OpenAlex

Introduction: Interferon (IFN)-free regimens using new direct acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C (HCV) infection and demonstrate a sustained viral response (SVR) of over 90%. A recent publication has suggested an association between DAA therapy and early hepatocellular carcinoma (HCC) recurrence raising concerns about their safety. Therefore, we conducted a retrospective study to investigate the impact of DAA initiation on early tumor recurrence after curative treatments in HCV-related HCC. Methods: From surgery and interventional radiology (January 2012-December 2015) databases, 103 unique HCV infected patients with primary or recurrent HCC were identified. Thirty-seven consecutive HCV infected patients with complete response to their curative HCC therapy for at least 3 months were identified, after excluding those who failed to achieve complete radiological response (n=19), received transarterial chemoembolization (TACE) (n=17), received anti-viral therapy prior to HCC diagnosis or therapy (n=14), received interferon containing DAA regimens (n=3), died within 3 months of HCC therapy (n=6), or those lost to follow-up (n=7). Fourteen of these patients subsequently received DAAs, and 23 acted as controls. To prevent crossover into the DAA treatment cohort, a maximum follow-up period of 36 months after the last HCC treatment was set. Results: Baseline age, gender, total bilirubin, albumin, MELD score, alpha-feto protein levels, total tumor volume, percentage of patients with primary HCC and prior interferon exposure did not differ. Both groups were predominately infected with genotype 1 (DAA 71% vs controls 70%). Median interval between HCC treatment and the start of DAA treatment was 11 months, but ranged from 2 to 17 months. The median observation period was 23 months in DAA and 17 months in controls. In the current observation period, HCC recurrence occurred in 5/14 (36%) treated with DAAs and 15/23 (65%) of controls. Kaplan-Meier analysis did not show improved HCC recurrence free survival in the DAA group (p=0.0639). BCLC staging of recurrent disease was similar in both groups (BCLC 0/A: DAA 60% vs controls 73%; BCLC B/C: DAA 40% vs controls 27%) Conclusion: In our analysis, DAA treatment after curative HCC therapy was not associated with early or more aggressive tumor recurrence. Ultimately, a randomized clinical trial should be performed to further clarify this controversial subject.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.297
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicHepatitis C virus research→French-language works237,207→